Eric A. Utt, Ph.D., Director, Worldwide Policy for Pfizer, wraps up the second of a two-part series on incremental innovation. During the 1940s and 1950s, tuberculosis patients were housed in sanitariums, frequently alongside patients who had been institutionalized with various mental illnesses. At this time, mental disorders such as schizophrenia and depression were not accessible [...]

A recent op-ed in Forbes offers a welcome rebuttal to misguided criticism of the conduct of clinical trials by the biopharmaceutical industry by refuting the notion that “medicine is broken” partly due to the hiding of “negative” clinical trial results.  First, it explains how even clinical trials that do not validate the premise that they [...]

As part of our ongoing incremental innovation series on the Catalyst, Thomas F. Goss, PharmD, Senior Vice President, Boston Healthcare Associates, highlights the importance of medical progress for patients suffering from rheumatoid arthritis in his very own blog post:  The weather is warming (finally) here in the northeast, and like many families, we found ourselves [...]